195 hawthorne partners LLC

133 norfolk street
attn: jerry atkins
new york, new york 10002

NYS Entity Status
ACTIVE

NYS Filing Date
SEPTEMBER 04, 2014

NYS DOS ID#
4631242

County
KINGS

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2014 - 195 HAWTHORNE PARTNERS LLC









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • The Top 10 Moments of New York Fashion Week
    By THE NEW YORK TIMES - Friday Sep 15, 2017

    Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.

    Source: NYT > Home Page
  • Women of Sex Tech, Unite
    By ANNA NORTH - Friday Aug 18, 2017

    New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.

    Source: NYT > Home Page
  • Trump admin blocks Chinese buyer from taking over US tech firm
    By Bob Fredericks - Wednesday Sep 13, 2017

    Citing national security concerns, President Trump on Wednesday blocked a Chinese-backed investor from buying Lattice Semiconductor Corp. — only the fourth time a president has stopped a foreign takeover in 27 years. The would-be buyer, Canyon Bridge Capital Partners LLC, is a private-equity firm backed by a Chinese state-owned asset manager, Bloomberg reported. “Consistent with...

    Source: New York Post: Business
  • Fit City: Taking Night-Life Cue, Gyms Lower the Lights
    By TATIANA BONCOMPAGNI - Tuesday Jun 13, 2017

    Cycling, boxing and running studios, as well as some full-service gyms, are using sophisticated lighting systems to heighten the exercise experience.

    Source: NYT > Home Page
  • Celgene Broadens Forma Deal, Adding $195M More for Drug R&D
    By Frank Vinluan - Tuesday Aug 29, 2017

    Celgene and Forma Therapeutics are expanding their already extensive relationship. The Summit, NJ-based drugmaker has exercised a $195 million option to widen the breadth of the 2014 deal it signed with Forma to co-develop drugs for cancer and other therapeutic areas—an agreement that gave Celgene (NASDAQ: CELG) the option to buy Forma down the road. […]

    Source: Xconomy New York